Vaccine against african swine fever virus infection
AssigneeThe Pirbright Institute
InventorsLinda Dixon, Ana Reis, Samuel Connell, Anusyah Rathakrishnan
Life of this patent
Estimating the term…
Abstract
The present invention relates to attenuated African Swine Fever Viruses. The attenuated viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent African Swine Fever.
Claims23
An attenuated African Swine Fever (ASF) virus in which the expression and/or activity of the following genes is disrupted:
- multigene-family (MGF) 360 12L, 13L and 14L, and
- MGF 505 1R,
- and which comprises a functional version of the following genes:
- (i) MGF 360 10L and/or 11L, and
- (ii) MGF 505 2R and/or 3R.
An attenuated ASF virus which lacks a functional version of the K145R gene and/or the B125R gene.
A method of attenuating an ASF virus which comprises the step of disrupting the expression and/or activity of the following genes:
- MGF 360 12L, 13L and 14L, and
- MGF 505 1R,
- whilst retaining the function of the following genes:
- (i) MGF 360 10L and/or 11L, and
- (ii) MGF 505 2R and/or 3R.
Dependencies are inferred from the claim text.